TipRanks

Notifications

J.P. Morgan Keeps Their Sell Rating on AnaptysBio (ANAB)

In a report released yesterday, Anupam Rama from J.P. Morgan maintained a Sell rating on AnaptysBio (ANABResearch Report), with a price target of $25.00. The company’s shares closed last Wednesday at $31.80.

According to TipRanks.com, Rama is a 4-star analyst with an average return of 6.6% and a 44.2% success rate. Rama covers the Healthcare sector, focusing on stocks such as Day One Biopharmaceuticals, Springworks Therapeutics, and Protagonist Therapeutics.

The word on The Street in general, suggests a Hold analyst consensus rating for AnaptysBio with a $34.33 average price target.

See today’s best-performing stocks on TipRanks >>

Based on AnaptysBio’s latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $20.89 million and GAAP net loss of $6.67 million. In comparison, last year the company had a GAAP net loss of $23.77 million.

Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ANAB in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

AnaptysBio, Inc. is a clinical stage biotechnology company, which engages in developing antibody product candidates focused on unmet medical needs in inflammation. Its pipeline includes ANB020, ANB019, and checkpoint receptor agonist antibodies. The company was founded by Andrew B. Cubitt, William J. Boyle and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.

Read More on ANAB:

Tags: